Alterity Therapeutics Future Growth
Future criteria checks 2/6
Alterity Therapeutics's earnings are forecast to decline at 19.5% per annum while its annual revenue is expected to grow at 76.7% per year.
Key information
-19.5%
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 31.5% |
| Revenue growth rate | 76.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Nov 2022 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2025 | 1 | -24 | N/A | N/A | 1 |
| 6/30/2024 | 3 | -21 | N/A | N/A | 1 |
| 6/30/2023 | 5 | -16 | N/A | N/A | 1 |
| 12/31/2022 | 5 | -14 | -14 | -14 | N/A |
| 9/30/2022 | 5 | -14 | -13 | -13 | N/A |
| 6/30/2022 | 5 | -13 | -12 | -12 | N/A |
| 3/31/2022 | 5 | -13 | -16 | -16 | N/A |
| 12/31/2021 | 5 | -13 | -19 | -19 | N/A |
| 9/30/2021 | 5 | -14 | -18 | -18 | N/A |
| 6/30/2021 | 4 | -15 | -17 | -17 | N/A |
| 3/31/2021 | 2 | -16 | -16 | -16 | N/A |
| 12/31/2020 | 0 | -16 | -14 | -14 | N/A |
| 9/30/2020 | 0 | -15 | -12 | -12 | N/A |
| 6/30/2020 | N/A | -13 | -9 | -9 | N/A |
| 3/31/2020 | 2 | -13 | -9 | -9 | N/A |
| 12/31/2019 | 4 | -13 | -9 | -9 | N/A |
| 9/30/2019 | 5 | -12 | -12 | -12 | N/A |
| 6/30/2019 | 5 | -12 | -14 | -14 | N/A |
| 3/31/2019 | 5 | -11 | -13 | -13 | N/A |
| 12/31/2018 | 4 | -10 | -12 | -12 | N/A |
| 9/30/2018 | 4 | -9 | -9 | -9 | N/A |
| 6/30/2018 | 3 | -8 | -6 | -6 | N/A |
| 3/31/2018 | 3 | -8 | -6 | -6 | N/A |
| 12/31/2017 | 3 | -8 | -6 | -6 | N/A |
| 9/30/2017 | 3 | -8 | -6 | -6 | N/A |
| 6/30/2017 | 3 | -8 | -6 | -6 | N/A |
| 3/31/2017 | 4 | -8 | -3 | -3 | N/A |
| 12/31/2016 | 4 | -9 | -1 | -1 | N/A |
| 9/30/2016 | 4 | -8 | N/A | -4 | N/A |
| 6/30/2016 | 5 | -8 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBN0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PBN0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PBN0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PBN0's revenue (76.7% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: PBN0's revenue (76.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PBN0's Return on Equity is forecast to be high in 3 years time